Jefferies Financial Group Reaffirms Buy Rating for Haleon (LON:HLN)

Haleon (LON:HLN)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Financial Group in a research report issued on Monday,London Stock Exchange reports. They currently have a GBX 450 price objective on the stock. Jefferies Financial Group’s price target would suggest a potential upside of 19.62% from the company’s current price.

A number of other analysts have also recently commented on the company. Deutsche Bank Aktiengesellschaft dropped their price target on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Berenberg Bank boosted their target price on Haleon from GBX 510 to GBX 512 and gave the stock a “buy” rating in a report on Thursday, March 19th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Haleon has an average rating of “Moderate Buy” and an average target price of GBX 407.

Haleon Stock Up 2.5%

Shares of Haleon stock traded up GBX 9.30 during trading on Monday, hitting GBX 376.20. The company’s stock had a trading volume of 20,708,824 shares, compared to its average volume of 35,200,227. Haleon has a 52 week low of GBX 325.10 and a 52 week high of GBX 419.50. The company has a market capitalization of £33.51 billion, a PE ratio of 20.34, a P/E/G ratio of 1.49 and a beta of 0.25. The company has a fifty day simple moving average of GBX 385.76 and a two-hundred day simple moving average of GBX 367.44. The company has a debt-to-equity ratio of 52.26, a quick ratio of 0.93 and a current ratio of 0.92.

Haleon (LON:HLN) last posted its quarterly earnings data on Thursday, February 26th. The company reported GBX 18.60 EPS for the quarter. Haleon had a net margin of 13.81% and a return on equity of 9.44%. Equities research analysts predict that Haleon will post 19.5033282 earnings per share for the current year.

Insider Buying and Selling at Haleon

In related news, insider Brian McNamara sold 63,012 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of GBX 368, for a total value of £231,884.16. 0.02% of the stock is owned by company insiders.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.